BTC$61,703.00-1.60%
ETH$1,651.63-1.20%
USDT$0.99870.00%
BNB$569.19-1.32%
USDC$0.9998+0.01%
XRP$1.08-1.71%
SOL$69.04-0.43%
TRX$0.3287-0.47%
FIGR_HELOC$1.03-0.65%
HYPE$63.55+2.01%
DOGE$0.0771-2.40%
USDS$0.9998+0.01%
RAIN$0.0159+1.39%
LEO$9.34-2.18%
ZEC$416.47+0.32%
XLM$0.1857-3.09%
BTC$61,703.00-1.60%
ETH$1,651.63-1.20%
USDT$0.99870.00%
BNB$569.19-1.32%
USDC$0.9998+0.01%
XRP$1.08-1.71%
SOL$69.04-0.43%
TRX$0.3287-0.47%
FIGR_HELOC$1.03-0.65%
HYPE$63.55+2.01%
DOGE$0.0771-2.40%
USDS$0.9998+0.01%
RAIN$0.0159+1.39%
LEO$9.34-2.18%
ZEC$416.47+0.32%
XLM$0.1857-3.09%
GE Aerospace delivered a strong Q4, posting $1.57 EPS and $11.87 billion in revenue as it heads into 2026 with upbeat growth plans.
McCormick reported Q4 revenue of $1.85 billion and EPS of $0.86, as the company pointed to a steady 2026 outlook focused on long-term growth and continued…
GameStop stock climbed in premarket trading after Ryan Cohen bought another 500,000 shares and increased his ownership in the company.
Moderna stock rose over 7% after the company and Merck said their personalized melanoma vaccine kept working at five years, cutting recurrence or death risk by…
Intel stock rose in premarket trading as investors looked ahead to Q4 earnings, betting CEO Lip-Bu Tan’s turnaround plan is gaining traction and data center demand…
Travelers posted a strong Q4 2025, reporting EPS of $11.13 on $12.43 billion in revenue, as the insurer benefited from solid underwriting results and higher investment…
Truist delivered Q4 EPS of $1.00 with $5.25 billion in revenue, while the bank highlighted strategic initiatives aimed at improving future performance.
Johnson & Johnson reported Q4 2025 revenue of $24.6 billion, beating expectations, while EPS came in at $2.46, just below forecasts.
Netflix fell in premarket despite beating Q4 estimates, as weaker growth trends and the Warner Bros. Discovery deal overhang pressured sentiment.
Despite surpassing its average analyst price target, Micron’s forward valuation and memory bottleneck economics point toward a credible path to $500 by 2026.
RAPT Therapeutics stock surged over 63% after GSK agreed to buy the company for $58 per share in a $2.2 billion deal.
With risk assets retreating and commodities exploding higher, investors are hunting for durable growth stories trading below consensus value.
ImmunityBio shares jumped in premarket trading after the FDA outlined next steps for expanding ANKTIVA’s bladder cancer label.